Alzinova publishes the Annual Report for 2019Date: 2020-04-15
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the Annual Report of the financial year 2019.
The Annual Report, which is attached in the press release, can also be downloaded from the company’s Swedish website, www.alzinova.se
For more information, please contact:
Kristina Torfgård, CEO
Telephone: +46 70 846 79 75
Corpura Fondkommission AB
About Alzinova AB
Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer’s disease – one of our major health scourges, without efficient treatment options. The Company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is currently under preclinical development, in preparation for human clinical trials. The Company further conducts development within diagnostics for the disease. Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.